

Early Elevation of Thioredoxin-I Serum Levels Predicts 28-Day Mortality in Patients with Sepsis [Corrigendum]

Li X, Shen H, Zhou T, et al. *J Inflamm Res.* 2021;14:3837–3848. The authors apologize for this error.

The authors have advised due to an error at the time of assembling the Tables, Table 1 on page 3841 is incorrect. The correct Table is as follows.

Table I Comparison of Baseline Clinical Characteristics Between Survivors and Non-Survivors

	Survivors	Non-Survivors	P value
Age (years)	65±16	68±13	0.172
Gender (male/female)	109/35	24/19	0.012
Coronary heart disease	45 (31.3%)	13 (30.2%)	0.899
Hypertension	38 (26.4%)	11 (25.6%)	0.916
Type 2 diabetes	15 (10.4%)	5 (11.6%)	0.822
Chronic renal failure	11 (7.8%)	4 (9.3%)	0.725
COPD	23 (16.0%)	8 (18.1%)	0.684
Length of ICU stay(days)	8 (3~21)	6 (2~22)	0.025
Survival days	28	10 (2~22)	0.000
Trx-I (ng/mL)	15.2 (2.3–789.5)	382.5 (7.5–1732.5)	0.000
Lac (mmol/L)	2.2 (0.5–11.0)	3.2 (0.9–18)	0.000
PCT (ng/mL)	4.10 (0.40–200.00)	13.9 (0.4–200.0)	0.000
CRP (mg/mL)	99.40 (7.48–200.0)	127.6 (18.6–468.0)	0.000
IL-6 (ng/mL)	74.6 (2.9–754.3)	376.3 (13.4–912.1)	0.000
ΔSOFA	6 (2–18)	11 (3–15)	0.000
HR (beats/min)	101±22	110±33	0.033
RR (beats/min)	24±6	24 (12–40)	0.048
MAP (mmHg)	84±18	70±17	0.000
Temperature	37.5±1.0	37.8±1.3	0.000
WBCs (10 ⁹)	15.1±8.0	13.5±6.4	0.222
HCT%	32.7±9.1	31.1±7.0	0.295
PLT (10 ⁹)	172 (21.0–527.0)	130.0 (17.0–364.0)	0.025

(Continued)

Table 1 (Continued).

	Survivors	Non-Survivors	P value
Scr (umol/L)	96.4 (33.7–507.6)	144.0 (44.9–1477.9)	0.002
TBIL(mmol/L)	17 (3.1–122.0)	19.6 (4.6–124.7)	0.029
PaO ₂ /FIO ₂ (mmHg)	187.8 (44.8–675.0)	150.2 (63.3–417.1)	0.001
GCS	12 (3–15)	9 (3–15)	0.000

Abbreviations: Trx-I, thioredoxin; Lac, lactate; PCT, procalcitonin; CRP, C-reactive protein; IL-6, interleukin-6; Δ SOFA, sequential organ failure assessment score; HR, heart rate; RR, respiratory rate; MAP, mean artery pressure; WBC, white blood cells; PLT, platelet; HCT, hematocrit; TBIL, total bilirubin; GCS, Glasgow Coma Score.

Journal of Inflammation Research

Dovepress

Publish your work in this journal

The Journal of Inflammation Research is an international, peer-reviewed open-access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis formation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular

mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflammation. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-inflammation-research-journal>

<https://doi.org/10.2147/JIR.S351869>